JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C)

Magrinat, 1992, Nitric oxide modulation of human leukemia cell differentiation and gene expression, Blood, 80, 1880, 10.1182/blood.V80.8.1880.1880 Shami, 1995, Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells, Leukemia Res, 19, 527, 10.1016/0145-2126(95)00013-E Shami, 1998, Schedule and concentration-dependent induction of apoptosis in leukemia cells by nitric oxide, Leukemia, 12, 1461, 10.1038/sj.leu.2401131 Moncada, 1991, Nitric oxide: physiology, pathophysiology, and pharmacology, Pharmacol Rev, 43, 109 Shami, 2003, JS-K, a glutathione S-transferase-activated nitric oxide donor with potent anti-neoplastic activity, Mol Cancer Ther, 2, 409 Baines, 1992, Multidrug resistance in leukaemia, Baillieres Clin Hematol, 5, 943, 10.1016/S0950-3536(11)80053-3 Sargent, 1999, Evidence for the involvement of the glutathione pathway in drug resistance in AML, Adv Exp Med Biol, 457, 205, 10.1007/978-1-4615-4811-9_22 Shami, 2006, Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo, J Med Chem, 49, 4356, 10.1021/jm060022h Saavedra, 2001, The secondary amine/nitric oxide complex ion R2N[N(O)NO]− as nucleophile and leaving group in SNAr reactions, J Org Chem, 66, 3090, 10.1021/jo0016529 Chou, 1984, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv Enzyme Regul, 22, 27, 10.1016/0065-2571(84)90007-4 Singh, 1988, A simple technique for quantitation of low levels of DNA damage in individual cells, Exp Cell Res, 175, 184, 10.1016/0014-4827(88)90265-0 Kiziltepe, 2007, JS-K, a GST-activated nitric oxide generator, induces DNA double strand breaks, activates DNA damage response pathways, and induces apoptosis in human multiple myeloma cells, Blood, 110, 709, 10.1182/blood-2006-10-052845 Townsend, 2006, A glutathione S-transferase π-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins, Mol Pharmacol, 69, 501, 10.1124/mol.105.018523 Udupi, 2006, JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells, Leukemia Res, 30, 1279, 10.1016/j.leukres.2005.12.007 Chu, 2001, Antimetabolites, 388 Nguyen, 1992, DNA damage and mutation in human cells exposed to nitric oxide in vitro, Proc Natl Acad Sci USA, 89, 3030, 10.1073/pnas.89.7.3030 Laval, 1994, Inhibition by nitric oxide of the repair protein, O6-methylguanine-DNA-methyltransferase, Carcinogenesis, 15, 443, 10.1093/carcin/15.3.443 Sidorkina, 2003, Inhibition of poly(ADP-ribose) polymerase (PARP) by nitric oxide and reactive nitrogen oxide species, Free Radic Biol Med, 35, 1431, 10.1016/j.freeradbiomed.2003.08.015 Graziewicz, 1996, Nitric oxide inhibits DNA ligase activity: potential mechanisms of NO-mediated DNA damage, Carcinogenesis, 17, 2501, 10.1093/carcin/17.11.2501 Wink, 1994, The Fpg protein, a DNA repair enzyme, is inhibited by the biomediator nitric oxide in vitro and in vivo, Carcinogenesis, 15, 2125, 10.1093/carcin/15.10.2125